These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33215275)

  • 1. Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
    Wei W; Li H; Zhang G; Zhang Y; Wu K; Bao R; Wang G; Zheng H; Xia Y; Li C
    Med Oncol; 2020 Nov; 37(12):116. PubMed ID: 33215275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.
    Zhang Y; Liu Q; Wei W; Zhang G; Yan S; Dai R; Sun Y; Su D; Lv S; Xia Y; Li J; Li C
    BMC Cancer; 2021 Oct; 21(1):1101. PubMed ID: 34645397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.
    Li C; Sun H; Wei W; Liu Q; Wang Y; Zhang Y; Lian F; Liu F; Li C; Ying K; Huo H; Qi Z; Li B
    Cell Oncol (Dordr); 2020 Dec; 43(6):1099-1116. PubMed ID: 32710433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
    Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F
    Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
    Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
    Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
    Yang W; Monroe J; Zhang Y; George D; Bremer E; Li H
    Cancer Lett; 2006 Nov; 243(2):217-27. PubMed ID: 16413676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling.
    Zhang Y; Yang B; Zhao J; Li X; Zhang L; Zhai Z
    Med Sci Monit; 2018 Jan; 24():294-304. PubMed ID: 29332931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
    Golden EB; Lam PY; Kardosh A; Gaffney KJ; Cadenas E; Louie SG; Petasis NA; Chen TC; Schönthal AH
    Blood; 2009 Jun; 113(23):5927-37. PubMed ID: 19190249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
    Gulla A; Morelli E; Johnstone M; Turi M; Samur MK; Botta C; Cifric S; Folino P; Vinaixa D; Barello F; Clericuzio C; Favasuli VK; Maisano D; Talluri S; Prabhala R; Bianchi G; Fulciniti M; Wen K; Kurata K; Liu J; Penailillo J; Bragoni A; Sapino A; Richardson PG; Chauhan D; Carrasco RD; Hideshima T; Munshi NC; Anderson KC
    Blood; 2024 Jun; 143(25):2612-2626. PubMed ID: 38551812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.
    Fu Z; Lu C; Zhang C; Qiao B
    Anticancer Drugs; 2019 Aug; 30(7):e0773. PubMed ID: 30807553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.
    Chandra A; Wang L; Young T; Zhong L; Tseng WJ; Levine MA; Cengel K; Liu XS; Zhang Y; Pignolo RJ; Qin L
    FASEB J; 2018 Jan; 32(1):52-62. PubMed ID: 28860152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
    Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
    Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling.
    Waad Sadiq Z; Brioli A; Al-Abdulla R; Çetin G; Schütt J; Murua Escobar H; Krüger E; Ebstein F
    Front Immunol; 2023; 14():982720. PubMed ID: 36936919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
    Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
    Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
    Miles MA; Harris MA; Hawkins CJ
    Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Weniger MA; Overbey J; Dunleavy K; Wilson WH; Wiestner A; Parekh S
    Oncotarget; 2015 Sep; 6(29):27332-42. PubMed ID: 25714012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
    Li Y; Dong S; Tamaskar A; Wang H; Zhao J; Ma H; Zhao Y
    Oncol Res; 2020 Dec; 28(5):497-507. PubMed ID: 32580819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab.
    Wang D; Xu Q; Yuan Q; Jia M; Niu H; Liu X; Zhang J; Young CY; Yuan H
    Oncogene; 2019 May; 38(18):3458-3474. PubMed ID: 30647455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.